Free Trial
→ Everyone’s watching Nvidia right now. Here’s why I’m excited. (From Timothy Sykes) (Ad) Buy ABVX Stock  Free ABVX Stock Alerts

ABIVAX Société Anonyme (ABVX) Financials

ABIVAX Société Anonyme logo
$5.69 +0.02 (+0.35%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$5.69 0.00 (0.00%)
As of 05/27/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for ABIVAX Société Anonyme

Annual Income Statements for ABIVAX Société Anonyme

This table shows ABIVAX Société Anonyme's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Income / (Loss) Attributable to Common Shareholders		 -182 -163 -65 -48
Consolidated Net Income / (Loss)		 -182 -163 -65 -48
Net Income / (Loss) Continuing Operations		 -182 -163 -65 -48
Total Pre-Tax Income 		-182 -163 -65 -48
Total Operating Income		 -179 -141 -69 -47
Total Gross Profit		 -6.16 -7.11 0.00 0.00
Total Revenue		 -6.16 -7.11 0.00 0.00
Operating Revenue		 -6.16 -7.11 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00
Total Operating Expenses		 173 134 69 47
Selling, General & Admin Expense		 34 25 8.01 6.32
Research & Development Expense		 152 114 52 54
Other Operating Expenses / (Income)		 -13 -5.11 -4.90 -14
Impairment Charge		 0.00 0.00 15 0.00
Total Other Income / (Expense), net		 -3.37 -23 4.38 -1.19
Interest Expense		 18 31 7.51 4.03
Interest & Investment Income		 14 8.31 12 2.84
Income Tax Expense		 0.00 0.00 0.00 0.00
Weighted Average Basic Shares Outstanding		 63.05M 43.07M 19.09M 15.46M
Diluted Earnings per Share		 ($2.90) ($3.79) ($3.40) ($2.75)
Weighted Average Diluted Shares Outstanding		 63.05M 43.07M 19.09M 15.46M
Weighted Average Basic & Diluted Shares Outstanding		 63.35M 62.93M - -

Quarterly Income Statements for ABIVAX Société Anonyme

No quarterly income statements for ABIVAX Société Anonyme are available.

Annual Cash Flow Statements for ABIVAX Société Anonyme

This table details how cash moves in and out of ABIVAX Société Anonyme's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Net Change in Cash & Equivalents		 -112 -144 -68 36
Net Cash From Operating Activities		 -154 -190 -58 -51
Net Cash From Continuing Operating Activities		 -154 -190 -58 -51
Net Income / (Loss) Continuing Operations		 -182 -163 -65 -48
Consolidated Net Income / (Loss)		 -182 -163 -65 -48
Depreciation Expense		 1.14 0.78 0.52 0.34
Non-Cash Adjustments To Reconcile Net Income		 26 -32 6.16 -1.70
Changes in Operating Assets and Liabilities, net		 1.47 4.14 0.08 -1.57
Net Cash From Investing Activities		 -0.66 -16 0.33 -7.05
Net Cash From Continuing Investing Activities		 -0.66 -16 0.33 -0.05
Purchase of Property, Plant & Equipment		 -0.66 - - -0.05
Acquisitions		 0.00 - - -
Sale and/or Maturity of Investments		 0.00 - - 0.00
Net Cash From Financing Activities		 38 62 -10 94
Net Cash From Continuing Financing Activities		 38 62 -10 72
Repayment of Debt		 -12 - -10 -2.44
Issuance of Debt		 50 62 0.00 -
Issuance of Common Equity		 0.45 - - 79
Effect of Exchange Rate Changes		 2.47 - - -
Cash Interest Paid		 7.97 - - -
Cash Interest Received		 8.47 2.65 0.02 -

Quarterly Cash Flow Statements for ABIVAX Société Anonyme

No quarterly cash flow statements for ABIVAX Société Anonyme are available.

Annual Balance Sheets for ABIVAX Société Anonyme

This table presents ABIVAX Société Anonyme's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Total Assets		 212 362 81 124
Total Current Assets		 169 306 39 85
Cash & Equivalents		 149 279 29 69
Accounts Receivable		 20 27 9.88 17
Plant, Property, & Equipment, net		 -3.51 -5.78 -0.80 0.23
Plant, Property & Equipment, gross		 -3.51 -5.78 -0.80 0.23
Total Noncurrent Assets		 220 218 105 74
Goodwill		 19 20 20 36
Intangible Assets		 189 171 72 48
Noncurrent Deferred & Refundable Income Taxes		 0.00 -0.06 -0.14 -0.18
Other Noncurrent Operating Assets		 11 27 13 -9.72
Total Liabilities & Shareholders' Equity		 385 518 143 124
Total Liabilities		 160 138 70 83
Total Current Liabilities		 69 88 38 24
Short-Term Debt		 22 33 21 0.71
Accounts Payable		 45 52 17 23
Other Current Liabilities		 1.21 2.85 0.00 0.00
Total Noncurrent Liabilities		 92 50 32 59
Long-Term Debt		 77 29 21 50
Noncurrent Employee Benefit Liabilities		 0.78 0.70 0.65 0.78
Other Noncurrent Operating Liabilities		 13 21 11 7.66
Total Equity & Noncontrolling Interests		 224 380 73 107
Total Preferred & Common Equity		 224 380 73 77
Total Common Equity		 224 380 73 77
Common Stock		 496 530 161 122
Retained Earnings		 -272 -150 -89 -45
Other Equity Adjustments		 -0.08 - - 0.00

Quarterly Balance Sheets for ABIVAX Société Anonyme

No quarterly balance sheets for ABIVAX Société Anonyme are available.

Annual Metrics And Ratios for ABIVAX Société Anonyme

This table displays calculated financial ratios and metrics derived from ABIVAX Société Anonyme's official financial filings.

Metric 2024 2023 2022 2021
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021
Growth Metrics		 - - - -
Revenue Growth		 13.37% 0.00% 0.00% 0.00%
EBITDA Growth		 -26.97% -103.54% -48.00% 0.00%
EBIT Growth		 -27.08% -103.14% -48.03% 0.00%
NOPAT Growth		 -27.08% -103.14% -48.03% 0.00%
Net Income Growth		 -11.62% -151.51% -35.24% 0.00%
EPS Growth		 23.61% -11.53% -23.71% 0.00%
Operating Cash Flow Growth		 19.02% -226.49% -14.20% 0.00%
Free Cash Flow Firm Growth		 21.87% -134.91% 0.00% 0.00%
Invested Capital Growth		 7.33% 89.88% 44.10% 0.00%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.88% 115.99% 93.68% 102.54%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -60.35% -72.19% -72.43% -45.01%
Cash Return on Invested Capital (CROIC)		 -81.34% -141.39% -103.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -60.35% -72.19% -60.58% -32.63%
Return on Equity Simple (ROE_SIMPLE)		 -81.28% -42.99% -89.42% -62.08%
Net Operating Profit after Tax (NOPAT)		 -125 -99 -49 -33
NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -42.76% -63.44% -96.09% -32.27%
Return On Investment Capital (ROIC_SIMPLE)		 -38.68% -22.34% -42.38% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -179 -141 -69 -47
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -178 -140 -69 -47
Valuation Ratios		 - - - -
Price to Book Value (P/BV)		 2.06 1.21 2.98 2.80
Price to Tangible Book Value (P/TBV)		 28.66 2.44 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.36 1.50 2.68 3.84
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - -
Debt to Equity		 0.44 0.16 0.58 0.48
Long-Term Debt to Equity		 0.34 0.08 0.28 0.47
Financial Leverage		 -0.44 -0.45 -0.19 -0.44
Leverage Ratio		 0.95 0.98 1.14 1.16
Compound Leverage Factor		 0.97 1.13 1.07 1.19
Debt to Total Capital		 30.73% 13.90% 36.57% 32.24%
Short-Term Debt to Total Capital		 6.89% 7.42% 18.64% 0.45%
Long-Term Debt to Total Capital		 23.84% 6.48% 17.93% 31.79%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 18.63%
Common Equity to Total Capital		 69.27% 86.10% 63.43% 49.13%
Debt to EBITDA		 -0.56 -0.44 -0.61 -1.09
Net Debt to EBITDA		 0.28 1.55 -0.19 0.38
Long-Term Debt to EBITDA		 -0.43 -0.20 -0.30 -1.08
Debt to NOPAT		 -0.79 -0.62 -0.86 -1.55
Net Debt to NOPAT		 0.40 2.20 -0.27 0.55
Long-Term Debt to NOPAT		 -0.62 -0.29 -0.42 -1.53
Altman Z-Score		 -2.31 0.84 -2.49 0.41
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 16.36% 27.50%
Liquidity Ratios		 - - - -
Current Ratio		 2.45 3.49 1.02 3.53
Quick Ratio		 2.45 3.49 1.02 3.53
Cash Flow Metrics		 - - - -
Free Cash Flow to Firm (FCFF)		 -137 -176 -75 0.00
Operating Cash Flow to CapEx		 -23,238.59% -1,207.53% 0.00% -95,846.09%
Free Cash Flow to Firm to Interest Expense		 -7.81 -5.70 -9.96 0.00
Operating Cash Flow to Interest Expense		 -8.75 -6.16 -7.75 -12.65
Operating Cash Flow Less CapEx to Interest Expense		 -8.79 -6.68 -7.71 -12.66
Efficiency Ratios		 - - - -
Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - -
Invested Capital		 175 163 86 59
Invested Capital Turnover		 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 12 77 26 0.00
Enterprise Value (EV)		 412 243 230 228
Market Capitalization		 461 461 217 217
Book Value per Share		 $3.57 $8.83 $3.81 $5.01
Tangible Book Value per Share		 $0.26 $4.39 ($1.00) ($0.45)
Total Capital		 324 441 115 158
Total Debt		 100 61 42 51
Total Long-Term Debt		 77 29 21 50
Net Debt		 -50 -217 13 -18
Capital Expenditures (CapEx)		 0.66 16 -0.33 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -27 -28 -6.68 -6.76
Debt-free Net Working Capital (DFNWC)		 122 251 22 62
Net Working Capital (NWC)		 100 218 0.80 61
Net Nonoperating Expense (NNE)		 57 65 16 15
Net Nonoperating Obligations (NNO)		 -50 -217 13 -47
Total Depreciation and Amortization (D&A)		 1.14 0.78 0.52 0.34
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 63.05M 43.07M 0.00 0.00
Adjusted Diluted Earnings per Share		 ($2.90) ($3.43) $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 63.05M 43.07M 0.00 0.00
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 63.35M 62.93M 0.00 0.00
Normalized Net Operating Profit after Tax (NOPAT)		 -125 -99 -38 -33
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - -
EBIT to Interest Expense		 -10.18 -4.57 -9.23 -11.63
NOPAT to Interest Expense		 -7.13 -3.20 -6.46 -8.14
EBIT Less CapEx to Interest Expense		 -10.22 -5.08 -9.19 -11.64
NOPAT Less CapEx to Interest Expense		 -7.16 -3.71 -6.42 -8.15
Payout Ratios		 - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% -9.78%

Quarterly Metrics And Ratios for ABIVAX Société Anonyme

No quarterly metrics and ratios for ABIVAX Société Anonyme are available.

Frequently Asked Questions About ABIVAX Société Anonyme's Financials

When does ABIVAX Société Anonyme's fiscal year end?

According to the most recent income statement we have on file, ABIVAX Société Anonyme's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has ABIVAX Société Anonyme's net income changed over the last 3 years?

ABIVAX Société Anonyme's net income appears to be on an upward trend, with a most recent value of -$182.43 million in 2024, rising from -$48.05 million in 2021. The previous period was -$163.43 million in 2023. See ABIVAX Société Anonyme's forecast for analyst expectations on what’s next for the company.

What is ABIVAX Société Anonyme's operating income?
ABIVAX Société Anonyme's total operating income in 2024 was -$179.05 million, based on the following breakdown:
  • Total Gross Profit: -$6.16 million
  • Total Operating Expenses: $172.89 million
How has ABIVAX Société Anonyme revenue changed over the last 3 years?

Over the last 3 years, ABIVAX Société Anonyme's total revenue changed from $0.00 in 2021 to -$6.16 million in 2024, a change of -616,298,500.0%.

How much debt does ABIVAX Société Anonyme have?

ABIVAX Société Anonyme's total liabilities were at $160.40 million at the end of 2024, a 16.0% increase from 2023, and a 93.9% increase since 2021.

How much cash does ABIVAX Société Anonyme have?

In the past 3 years, ABIVAX Société Anonyme's cash and equivalents has ranged from $28.83 million in 2022 to $278.70 million in 2023, and is currently $149.28 million as of their latest financial filing in 2024.

How has ABIVAX Société Anonyme's book value per share changed over the last 3 years?

Over the last 3 years, ABIVAX Société Anonyme's book value per share changed from 5.01 in 2021 to 3.57 in 2024, a change of -28.8%.


Related Companies

This page (NASDAQ:ABVX) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
AI Meltdown Imminent: Dump These Stocks Now!
If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...
Paradigm Press | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...
Timothy Sykes | Sponsored
Do You Believe In President Trump? Answer This 1 Question
They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...
Colonial Metals | Sponsored